[HTML][HTML] Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

J Custers, D Kim, M Leyssen, M Gurwith, F Tomaka… - Vaccine, 2021 - Elsevier
Replication-incompetent adenoviral vectors have been under investigation as a platform to
carry a variety of transgenes, and express them as a basis for vaccine development. A …

Ebola virus vaccines: an overview of current approaches

A Marzi, H Feldmann - Expert review of vaccines, 2014 - Taylor & Francis
Ebola hemorrhagic fever is one of the most fatal viral diseases worldwide affecting humans
and nonhuman primates. Although infections only occur frequently in Central Africa, the …

Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R Bos, L Rutten, JEM van der Lubbe, MJG Bakkers… - npj Vaccines, 2020 - nature.com
Abstract Development of effective preventative interventions against SARS-CoV-2, the
etiologic agent of COVID-19 is urgently needed. The viral surface spike (S) protein of SARS …

[HTML][HTML] Immunogenicity and efficacy of one and two doses of Ad26. COV2. S COVID vaccine in adult and aged NHP

L Solforosi, H Kuipers, M Jongeneelen… - Journal of Experimental …, 2021 - rupress.org
Safe and effective coronavirus disease–19 (COVID-19) vaccines are urgently needed to
control the ongoing pandemic. While single-dose vaccine regimens would provide multiple …

A double-blind, randomized, placebo-controlled phase 1 study of Ad26. ZIKV. 001, an Ad26-vectored anti–Zika virus vaccine

NC Salisch, KE Stephenson, K Williams… - Annals of internal …, 2021 - acpjournals.org
Background: Zika virus (ZIKV) may cause severe congenital disease after maternal–fetal
transmission. No vaccine is currently available. Objective: To assess the safety and …

Ad26. COV2. S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease

JEM van Der Lubbe, SK Rosendahl Huber, A Vijayan… - npj Vaccines, 2021 - nature.com
Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26)
vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26. COV2. S) is …

Booster with Ad26. COV2. S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques

L Solforosi, LMM Costes, JTBM Tolboom… - Nature …, 2023 - nature.com
Omicron spike (S) encoding vaccines as boosters, are a potential strategy to improve COVID-
19 vaccine efficacy against Omicron. Here, macaques (mostly females) previously …

Safety and immunogenicity of a 2-dose heterologous vaccine regimen with Ad26. ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 …

G Mutua, O Anzala, K Luhn, C Robinson… - The Journal of …, 2019 - academic.oup.com
Abstract Background During the 2014 West African Ebola outbreak, Ebola vaccine
development was accelerated. The phase 1 VAC52150EBL1003 study was performed to …

[HTML][HTML] Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens

L Coughlan, EJ Kremer, DM Shayakhmetov - Molecular Therapy, 2022 - cell.com
Zoonotic viruses continually pose a pandemic threat. Infection of humans with viruses for
which we typically have little or no prior immunity can result in epidemics with high morbidity …

Adenovirus-based vaccines for fighting infectious diseases and cancer: progress in the field

D Majhen, H Calderon, N Chandra, CA Fajardo… - Human gene …, 2014 - liebertpub.com
The field of adenovirology is undergoing rapid change in response to increasing
appreciation of the potential advantages of adenoviruses as the basis for new vaccines and …